

Karen P Hayhurst

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6690784/publications.pdf>

Version: 2024-02-01

27
papers

1,701
citations

1051969

10
h-index

651938

25
g-index

27
all docs

27
docs citations

27
times ranked

1827
citing authors

#	ARTICLE	IF	CITATIONS
1	Tobacco Smoking Rates in a National Cohort of People with Substance Use Disorder Receiving Treatment. <i>European Addiction Research</i> , 2021, 27, 151-155.	1.3	4
2	Associations between participant characteristics, digital intervention engagement and recovery outcomes for participants accessing "Breaking Free Online" at "Change Grow Live". <i>Journal of Substance Use</i> , 2021, 26, 497-504.	0.3	5
3	Estimates of the Incidence of Crack Cocaine Use in Those Likely to Attend Treatment in the English Population, 2005-2018. <i>European Addiction Research</i> , 2021, 27, 83-86.	1.3	1
4	Components, impacts and costs of dementia home support: a research programme including the DESCANT RCT. <i>Programme Grants for Applied Research</i> , 2021, 9, 1-132.	0.4	6
5	Peaks in substance use prior to treatment presentation - a re-evaluation. <i>Addiction Research and Theory</i> , 2019, 27, 285-293.	1.2	1
6	Prevalence of alcohol, smoking, and illicit drug use amongst people with intellectual disabilities: review. <i>Drugs: Education, Prevention and Policy</i> , 2019, 26, 365-384.	0.8	7
7	Prevalence of recent fentanyl use among treated users of illicit opioids in England: based on piloted urine drug screens. <i>Clinical Toxicology</i> , 2019, 57, 368-371.	0.8	4
8	The effectiveness of diversion programmes for offenders using Class A drugs: a systematic review and meta-analysis. <i>Drugs: Education, Prevention and Policy</i> , 2019, 26, 113-124.	0.8	8
9	Unmet supportive care needs, health status and minimum costs in survivors of malignant melanoma. <i>European Journal of Cancer Care</i> , 2018, 27, e12811.	0.7	7
10	Development of a resource allocation formula for substance misuse treatment services. <i>Journal of Public Health</i> , 2018, 40, e396-e404.	1.0	2
11	Insights into the link between drug use and criminality: Lifetime offending of criminally-active opiate users. <i>Drug and Alcohol Dependence</i> , 2017, 179, 309-316.	1.6	40
12	Pathways through opiate use and offending: A systematic review. <i>International Journal of Drug Policy</i> , 2017, 39, 1-13.	1.6	44
13	Short-Term Outcomes for Opiate and Crack Users Accessing Treatment: The Effects of Criminal Justice Referral and Crack Use. <i>European Addiction Research</i> , 2016, 22, 145-152.	1.3	9
14	Quantifying crime associated with drug use among a large cohort of sanctioned offenders in England and Wales. <i>Drug and Alcohol Dependence</i> , 2015, 155, 52-59.	1.6	30
15	Patients' subjective rating of mental health improvement in a randomised controlled trial. <i>Psychiatry Research</i> , 2015, 229, 593-595.	1.7	5
16	The effectiveness and cost-effectiveness of diversion and aftercare programmes for offenders using class A drugs: a systematic review and economic evaluation. <i>Health Technology Assessment</i> , 2015, 19, 1-168.	1.3	28
17	Factors associated with receipt of residential rehabilitation by opiate users indicate that these clients are more amenable to drug treatment. <i>Drugs: Education, Prevention and Policy</i> , 2014, 21, 165-172.	0.8	1
18	Validity of subjective versus objective quality of life assessment in people with schizophrenia. <i>BMC Psychiatry</i> , 2014, 14, 365.	1.1	47

#	ARTICLE	IF	CITATIONS
19	Improved quality of life over one year is associated with improved adherence in patients with schizophrenia. <i>European Psychiatry</i> , 2014, 29, 191-196.	0.1	40
20	Drug spend and acquisitive offending by substance misusers. <i>Drug and Alcohol Dependence</i> , 2013, 130, 24-29.	1.6	17
21	Sexual function of patients with schizophrenia receiving first-generation (FGA) or second-generation antipsychotic (SGA) treatment. <i>International Journal of Psychiatry in Clinical Practice</i> , 2012, 16, 148-152.	1.2	5
22	The ANNSERS (Antipsychotic Non-Neurological Side Effects Rating Scale): validation of sexual side-effect measurement. <i>Therapeutic Advances in Psychopharmacology</i> , 2011, 1, 97-100.	1.2	14
23	Patient factors associated with receipt of combination antipsychotic drug therapy in the treatment of schizophrenia. <i>Journal of Psychopharmacology</i> , 2010, 24, 83-89.	2.0	6
24	Randomized Controlled Trial of the Effect on Quality of Life of Second- vs First-Generation Antipsychotic Drugs in Schizophrenia. <i>Archives of General Psychiatry</i> , 2006, 63, 1079.	13.8	1,031
25	Practicalities of running non-commercial clinical drug trials in the NHS: A resource based on the experiences of the CULASS study (Cost utility of the latest antipsychotics in severe schizophrenia). <i>Journal of Mental Health</i> , 2005, 14, 331-341.	1.0	0
26	Randomized Controlled Trial of Effect of Prescription of Clozapine Versus Other Second-Generation Antipsychotic Drugs in Resistant Schizophrenia. <i>Schizophrenia Bulletin</i> , 2005, 32, 715-723.	2.3	339
27	The shift from face-to-face to remote care during the COVID-19 pandemic: a qualitative survey analysis of users of UK drug and alcohol services. <i>Drugs: Education, Prevention and Policy</i> , 0, , 1-9.	0.8	0